Medication info
Glufomin Sustained Release Tablet 500mg (Metformin Hydrochloride)

Glufomin Sustained Release Tablet 500mg (Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Boryung Biopharma Co., Ltd.
Appearance
White, double convex, oblong sustained release tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 201906865 · Approved 2019.09.26 · Insurance code 670501860

Summary

Main use
Treatment of type 2 diabetes mellitus in adults
Who takes it
Adults
Adult dose
The dose should be determined individually based on therapeutic response and tolerability, and should not exceed the recommended maximum daily dose. - The usual starting dose is one 500mg extended-release metformin hydrochloride tablet once daily with the evening meal. - Blood glucose levels should be measured after one week and the dose adjusted. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. - When increasing the dose, increase by 500mg each week; up to a maximum of 2000mg per day may be taken with the evening meal. If glycemic control is not achieved with a maximum of 2000mg once daily, consider administering 1000mg twice daily; both doses should be taken with meals. - For patients already being treated with metformin tablets, the initial dose of this formulation is the same as the daily dose of immediate-release metformin tablets. Switching to this formulation is not recommended for patients taking 2000mg or more per day of immediate-release metformin tablets. - At treatment initiation and during dose adjustment, fasting blood glucose should be measured to assess the response to this medicine and determine the minimum effective dose. Blood glycated hemoglobin levels should be measured approximately every 3 months. - The goal of treatment with this medicine, whether administered as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and blood glycated hemoglobin levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. - The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be closely monitored every 3- 6 months. If creatinine clearance or glomerular filtration rate falls below 45ml/min or 45ml/min/1.73m2, respectively, this medicine should be discontinued immediately.

Ingredients

Manufacturer
Boryung Biopharma Co., Ltd.

Efficacy & effects

Treatment of type 2 diabetes mellitus in adults

  • Type 2 diabetes with insufficient blood sugar control
View approved original text

This medication is used to treat adults with type 2 diabetes whose blood sugar control is insufficient through diet and exercise alone, especially for overweight diabetes patients. This drug may be taken alone or in conjunction with other oral antidiabetic agents or insulin to help control blood sugar more effectively.

How to take

Adult dose

The dose should be determined individually based on therapeutic response and tolerability, and should not exceed the recommended maximum daily dose. - The usual starting dose is one 500mg extended-release metformin hydrochloride tablet once daily with the evening meal. - Blood glucose levels should be measured after one week and the dose adjusted. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. - When increasing the dose, increase by 500mg each week; up to a maximum of 2000mg per day may be taken with the evening meal. If glycemic control is not achieved with a maximum of 2000mg once daily, consider administering 1000mg twice daily; both doses should be taken with meals. - For patients already being treated with metformin tablets, the initial dose of this formulation is the same as the daily dose of immediate-release metformin tablets. Switching to this formulation is not recommended for patients taking 2000mg or more per day of immediate-release metformin tablets. - At treatment initiation and during dose adjustment, fasting blood glucose should be measured to assess the response to this medicine and determine the minimum effective dose. Blood glycated hemoglobin levels should be measured approximately every 3 months. - The goal of treatment with this medicine, whether administered as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and blood glycated hemoglobin levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. - The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be closely monitored every 3- 6 months. If creatinine clearance or glomerular filtration rate falls below 45ml/min or 45ml/min/1.73m2, respectively, this medicine should be discontinued immediately.

Precautions

This medication can rarely cause a serious condition called lactic acidosis, so if these symptoms occur, immediate notification to medical personnel is required. Caution is necessary as hypoglycemia may occur when used in combination with other diabetes medications. This medication should not be used in patients with moderate to severe renal impairment or acute illness. It is also safer for patients with heart-related diseases such as heart failure or acute myocardial infarction not to take this medication. Before and after examinations using iodinated contrast agents, this medication should be discontinued due to the risk of renal function deterioration and lactic acidosis and should be resumed after a certain period. Patients who are allergic to any components of this medication or who have type 1 diabetes should not use it. This medication should also be temporarily stopped in cases of severe infections, systemic disorders, and before and after surgery. Patients with poor nutritional status, liver function impairment, and excessive alcohol intake should also use caution with this medication. This medication can cause gastrointestinal disturbances, taste alteration, vitamin B12 deficiency, and especially, digestive symptoms are commonly seen at the onset of treatment. Regularly monitor renal function to reduce the risk of accumulation and side effects of this medication, and discontinue use if renal function declines. Caution is needed due to the risk of hypoglycemia in cases of irregular meals, vigorous exercise, and combination with other medications. During pregnancy, careful consideration is required regarding the effects on the fetus, and its use during breastfeeding is not recommended. Elderly individuals may have a risk of reduced renal function; thus, dose adjustment and regular function monitoring are necessary. In cases of overdose, blood dialysis can be used to remove the drug, so inform medical personnel immediately. This medication should be swallowed whole and should not be chewed or crushed, and the tablet shell may appear in the stool, which is normal. This medication can interact with other drugs, so inform medical personnel of any other medications being taken, and regularly check blood sugar and renal function. While taking this medication, excessive alcohol consumption should be avoided, and regular monitoring of blood sugar and health status is important.

Side effects

  • Lactic acidosis
  • severe hypoglycemia
  • vitamin B12 deficiency
  • taste impairment
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • anorexia
  • erythema
Show 3 more
  • pruritus
  • urticaria
  • rash

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a closed container. It is recommended to maintain a storage temperature between 1 degree and 30 degrees Celsius room temperature. Storing it this way helps maintain the effectiveness of the medication.

Appearance and packaging

Appearance

White, double convex, oblong sustained release tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.